MEsenchymal StEm Cells for Multiple Sclerosis

NCT ID: NCT01854957

Last Updated: 2013-05-16

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2014-09-30

Brief Summary

A double-blind, randomized, cross-over phase I/II study to evaluate the safety and the efficacy of the intravenous administration of autologous Mesenchymal Stem Cells (MSC) to patients with active multiple sclerosis (MS) resistant to currently available therapies.

Detailed Description

The mechanism of action of MSC relies on their ability to modulate pathogenic immune responses and provide neuroprotection through the release of anti-apoptotic, anti-oxidant and trophic factors as demonstrated by in vitro and in vivo preclinical studies.

Patients will be randomized to receive immediate vs. delayed treatment with either a dose equal to 1-2 millions/kg of body weight of autologous MSC, or equivalent volume of suspension media at baseline. At 6 months treatments will be reversed.

The primary outcome of this study is to evaluate

• treatment's safety within one year from MSC administration by measuring the the number, time-frame and severity of adverse event and
• treatment's activity in terms of reduction in the total number of contrast-gadolinium enhancing lesions (GEL) by magnetic resonance imaging (MRI) scans.

Secondary outcomes are to gain preliminary information on the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Autologous Mesenchymal Stem Cells

At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0

Group Type: EXPERIMENTAL

Autologous Mesenchymal Stem Cells

Intervention Type: BIOLOGICAL

Single dose of 1-2 x 1000000 cells/Kg body weight

Suspension media

At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0

Group Type: PLACEBO_COMPARATOR

No interventions assigned to this group

Interventions

Autologous Mesenchymal Stem Cells

Single dose of 1-2 x 1000000 cells/Kg body weight

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• 1. Diagnosis of MS

a. Relapsing remitting MS (RRMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by one or more of the following: i. ≥1 clinically documented relapse in past 12 months

ii. ≥2 clinically documented relapses in last 24 months

iii. ≥1 GEL at MRI performed within the last 12 months

b. Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod) as evidenced by both:

i. an increase of ≥1 point of the expanded disability status scale (EDSS) (if at randomization EDSS ≤ 5.0) or 0.5 EDSS point (if at randomization EDSS ≥ 5.5) in the last 12 months

ii. ≥1 clinically documented relapse or ≥ 1 GEL at MRI within the last twelve months.

c. Primary progressive MS (PPMS) patients with all the following features:

i. an increase of ≥1 EDSS point (if at randomization EDSS ≤ 5.0) or 0.5 EDSS point (if at randomization EDSS ≥5.5), in the last twelve months

ii. ≥ 1 GEL at MRI performed within the last 12 months

iii. positive cerebrospinal fluid (CSF) (oligoclonal banding

• 2. Age 18 to 50 years
• 3. Disease duration 2 to 10 years (included)
• 4. EDSS 3.0 to 6.5

• 4. Any active or chronic infection including infection with HIV1-2 or chronic Hepatitis B or Hepatitis C
• 5. Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization
• 6. Treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization
• 7. Treatment with corticosteroids within the 30 days prior to randomization
• 8. Relapse occurred during the 60 days prior to randomization
• 9. Previous history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year
• 10. Severely limited life expectancy by another co-morbid illness
• 11. History of previous diagnosis of myelodysplasia or previous hematologic disease or current clinically relevant abnormalities of white blood cell counts
• 12. Pregnancy or risk or pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study)
• 13. eGFR < 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination.
• 14. Inability to give written informed consent in accordance with research ethics board guidelines

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Azienda Ospedaliera Universitaria Integrata Verona

OTHER

Sponsor Role: collaborator

Ospedale San Raffaele

OTHER

Sponsor Role: collaborator

Antonio Uccelli

OTHER

Sponsor Role: lead

Responsible Party

Antonio Uccelli

MD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Giancarlo Comi, MD

Role: PRINCIPAL_INVESTIGATOR

Ospedale San Raffaele

Bruno Bonetti, MD

Role: PRINCIPAL_INVESTIGATOR

Azienda Ospedaliera Universitaria Integrata di Verona

Locations

University of Genova

Genova, Genova, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Antonio Uccelli, MD

Role: CONTACT

MESEMS@unige.it

+390103537028

References

Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022 Mar;59:103535. doi: 10.1016/j.msard.2022.103535. Epub 2022 Jan 19.

Reference Type: DERIVED

PMID: 35078125 (View on PubMed)

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

Reference Type: DERIVED

PMID: 31072380 (View on PubMed)

Other Identifiers

2011-001295-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MESEMS

Identifier Type: -

Identifier Source: org_study_id